H.C. Wainwright lowered the firm’s price target on Prelude Therapeutics to $5 from $6 and keeps a Buy rating on the shares. The analyst says the AbCellera collaboration potentially broadens the patient population for Prelude’s SMARCA2 degraders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRLD:
- Prelude Therapeutics price target lowered to $3 from $5 at Barclays
- Prelude Therapeutics updates pipeline ‘s clinical progress, prioritization
- Prelude, AbCellera team on precision antibody drug conjugates in oncology
- Prelude Therapeutics reports Q3 EPS (45c), consensus (58c)
- Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
